Erratum: Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study (The Lancet (2017) 389(10075) (1206–1217)(S0140673617304014)(10.1016/S0140-6736(17)30401-4));Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study

The Lancet

Volumn 389, Issue 10075, 2017, Pages 1206-1217

  Aletaha, Daniel ^a   Bingham, Clifton O ^b   Tanaka, Yoshiya ^c   Agarwal, Prasheen ^d   Kurrasch, Regina ^e   Tak, Paul P ^f   Popik, Sharon ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e GLAXOSMITHKLINE   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CHOLESTEROL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; PLACEBO; RHEUMATOID FACTOR; SIRUKUMAB; TRIACYLGLYCEROL; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BILIRUBIN BLOOD LEVEL; BREAST CARCINOMA; BRONCHITIS; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DERMATITIS; DIABETES MELLITUS; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH STATUS; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INTENTION TO TREAT ANALYSIS; LEUKOCYTE COUNT; LUNG ADENOCARCINOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; METASTATIC BREAST CANCER; MIDDLE AGED; MULTICENTER STUDY; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; OROPHARYNX SQUAMOUS CELL CARCINOMA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STEADY STATE; SUDDEN DEATH; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85012898645     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31299-0     Document Type: Erratum

References (28)

1. 1 Chen, YF, Jobanputra, P, Barton, P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10 (2006), 1–229.
2. 2 Emery, P, Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford) 51:suppl 5 (2012), v22–v30.
3. 3 Tak, PP, A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford) 51 (2012), 600–609.
4. 4 Du Pan, SM, Scherer, A, Gabay, C, Finckh, A, Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 71 (2012), 997–999.
5. 5 Kekow, J, Mueller-Ladner, U, Schulze-Koops, H, Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFalpha blocker failure. Biologics 6 (2012), 191–199.
6. 6 Akira, S, Taga, T, Kishimoto, T, Interleukin-6 in biology and medicine. Adv Immunol 54 (1993), 1–78.
7. 7 Tanaka, Y, Takeuchi, T, Amano, K, et al. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Mod Rheumatol 24 (2014), 399–404.
8. 8 Emery, P, Keystone, E, Tony, HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (2008), 1516–1523.
9. 9 Genovese, MC, Fleischmann, R, Kivitz, AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol 67 (2015), 1424–1437.
10. 10 Kivitz, A, Olech, E, Borofsky, M, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66 (2014), 1653–1661.
11. 11 Fleischmann, R, van Adelsberg, J, Lin, Y, et al. Sarilumab and non-biologic disease-modifying antirheumatic drugs in patients with active RA and inadequate response or intolerance to TNF inhibitors. Arthritis Rheumatol 69 (2017), 277–290.
12. 12 Xu, Z, Bouman-Thio, E, Comisar, C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 72 (2011), 270–281.
13. 13 Tanaka, Y, Martin Mola, E, IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis 73 (2014), 1595–1597.
14. 14 Smolen, JS, Weinblatt, ME, Sheng, S, Zhuang, Y, Hsu, B, Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 73 (2014), 1616–1625.
15. 15 Smolen, JS, Aletaha, D, McInnes, IB, Rheumatoid arthritis. Lancet 388 (2016), 2023–2038.
16. 16 Genovese, MC, McKay, JD, Nasonov, EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 58 (2008), 2968–2980.
17. 17 Services USDoHaH. Common terminology criteria for adverse events (CTCAE) version 4.03. http://evs.nci.nih.gov/ftp1/CTCAE/About.html (accessed Jan 24, 2017).
18. 18 Kosinski, M, Zhao, SZ, Dedhiya, S, Osterhaus, JT, Ware, JE Jr, Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 43 (2000), 1478–1487.
19. 19 Sampson, HA, Munoz-Furlong, A, Campbell, RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—second national Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 11 (2006), 391–397.
20. 20 Hsu, B, Wang, D, Sun, Y, et al. Improvement in measures of depressed mood and anhedonia, and fatigue, in a randomized, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 antibody, in patients with rheumatoid arthritis. Ann Rheum Dis 74 (2015), 720–721.
21. 21 Haapakoski, R, Mathieu, J, Ebmeier, KP, Alenius, H, Kivimaki, M, Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 49 (2015), 206–215.
22. 22 Lindqvist, D, Janelidze, S, Hagell, P, et al. Interleukin-6 Is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatriy 66 (2009), 287–292.
23. 23 Matcham, F, Rayner, L, Steer, S, Hotopf, M, The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 52 (2013), 2136–2148.
24. 24 Shetty, A, Hanson, R, Korsten, P, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther 8 (2014), 349–364.
25. 25 Klareskog, L, van der Heijde, D, de Jager, JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004), 675–681.
26. 26 Lipsky, PE, van der Heijde, DM, St Clair, EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (2000), 1594–1602.
27. 27 Weinblatt, ME, Keystone, EC, Furst, DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (2003), 35–45.
28. 28 Hunter, CA, Jones, SA, IL-6 as a keystone cytokine in health and disease. Nat Immunol 16 (2015), 448–457.